International Ophthalmology

, Volume 14, Issue 5–6, pp 303–308

The natural history of uveitis

  • Robert B. Nussenblatt
Article

Summary

Inflammatory diseases of the eye were known to the ancients, but only recently have the underlying mechanisms to this problem become better defined. During the middle portion of this century, most cases of uveitis thought to be caused by infectious agents, such as those responsible for syphilis and tuberculosis. Since then, it has become clear that endogenous mechanisms of immunomodulation play an important role in these disorders, which along with environmental and genetic factors make up an important triad. Animals studies have indicated the pivotal role of the T-cell in many of these disorders. The development of T-cell lines has helped to further delineate cell to cell interactions that occur during an ocular inflammatory event. The presence in the eye of uveitogenic antigens raises the strong possibility of autoimmune driven processes as well, similar to what is seen in the animal models. The better understanding of ocular inflammatory mechanisms has led to improved therapeutic strategies, including Sandimmune, and more recently Cyclosporine G, a related compound that may be less nephrotoxic. Newer therapeutic strategies will focus on even more novel modes of immunomodulation, probably without the use of medications.

Key words

uveitis T-cell Sandimmune S-antigen EAU HLA cyclosporine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Duke-Elder S, Perkins ES. System of Ophthalmology. Volume IX. Diseases of the Uveal Tract. St. Louis, CV Mosby Company 1966: 358–359.Google Scholar
  2. 2.
    Uhlenhuth PT. Zur lehre von unterscheidung verschiedener eiweissarten mit hilfe spezifischer sera. In: Festschrift zum 60 geburtstag von Robert Koch. Jena, German Democratic Republic, Fischer. 1903: 49–74.Google Scholar
  3. 3.
    Elschnig A. Studien zur sympatischen ophthalmis. Die antigene Wirkung des augenpigmentes. Albrecht von Graefes Arch Ophthalmol 1910; 76: 509–546.Google Scholar
  4. 4.
    Schlaegel TF Jr. Essentials of Uveitis. Boston, Little, Brown and Company. 1969: 27.Google Scholar
  5. 5.
    O'Connor GR. Factors related to the initiation and recurrences of uveitis, XL Edward Jackson memorial lecture. Am J Ophthalmol 1983; 96: 577–599.Google Scholar
  6. 6.
    Dernouchamps JP, Vaerman JP, Michiels J, Masson PL. Immune complexes in the aqueous humor and serum. Am J Ophthalmol 1977; 84: 24–31.Google Scholar
  7. 7.
    Kasp-Grochowska E, Graham E, Sanders MD, Dumonde DC, de Kozak Y, Van Tuyen V, Faure JP. Autoimmunity and circulating immune complexes in retinal vasculitis. Trans Ophthalmol Soc UK 1981; 101: 342–348.Google Scholar
  8. 8.
    Caspi RR, Roberge FG, Nussenblatt RB. Organ-resistant nonlymphoid cells suppress proliferation of autoimmune T-helper lymphocytes. Science 1987; 237: 1029–1032.Google Scholar
  9. 9.
    Ebringer A, Baines M, Ptaszynska T. Spondyloarthritis, uveitis, HLA-27, and Klebsiella. Immunol Rev 1985; 86: 101–116.Google Scholar
  10. 10.
    McGuigan LE, Geczy AF, Edmonds JP. The immunopathology of ankylosing spondylitis—a review. Semin Arthritis Rheum 1985; 15: 81–105.Google Scholar
  11. 11.
    Aguettaz JM, Vadot E, Mouillon M, Bonnet JL. Epiodemiological approach of the role of Chlamydiae in uveitis. J Fr Ophthalmol 1987; 10: 679–682.Google Scholar
  12. 12.
    Davies UM, Palmer RG, Denman AM. Treatment of acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial. Br J Rheumatol 1988; 27: 300–302.Google Scholar
  13. 13.
    Nussenblatt RB, Palestine AG. Uveitis. Fundamentals and Clinical Practice. Chicago: Year Book Medical Publishers, 1989.Google Scholar
  14. 14.
    Hirohata T, Kuratsume M, Nomura A. Prevalience of Behçet's syndrome in Hawaii. Hawaii Med J 1975; 34:244–246.Google Scholar
  15. 15.
    Namba K, Ueno Okito M. Behçet's disease and streptococcal infection. Jpn J Ophthalmol 1986; 30: 385–401.Google Scholar
  16. 16.
    Silveira C, Beifort R Jr, Burnier M Jr, Nussenblatt RB. Familial or ocular toxoplasmosis in 30 siblings. Identification of retinal toxoplasmic cysts in non-twin siblings and pseudo-unilateral retinitis pigmentosa secondary to ocular toxoplasmosis. Invest Ophthalmol Vis Sci 1987; 28 (suppl 3): 104.Google Scholar
  17. 17.
    Nussenblatt RB, Mittal KK, Fuhrman S, Sharma SD, Palestine AG. Ocular Toxoplasmosis: Lymphocyte proliferation in response to parasite and retinal antigens. Am J Ophthalmol 1989; 107: 632–641.Google Scholar
  18. 18.
    Benacerraf B, Green I, Paul WE. The immune response of guinea pigs to hapten-poly-L-lysine conjugates as an example of the genetic control of the recognition of antigenicity. Cold Spring Harbor Symp Quant Biol 1967; 32: 471–481.Google Scholar
  19. 19.
    Nussenblatt RB, Mittal KK, Ryan S, Green WR, Maumenee AE. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol 1982; 94: 147–158.Google Scholar
  20. 20.
    Ohno S, Matsuda H. Studies of HLA antigens in Behçet's disease in Japan. In: Lehner T, Barnes CG (eds). Recent Advances in Behçet's Disease. London: Royal Society of Medicine Services, 1986: 11–16.Google Scholar
  21. 21.
    Ohno S. Immunological aspects of Behçet's and Vogt-Koyanagi-Harada's disease. Trans Ophthalmol Soc UK 1981; 101: 335–341.Google Scholar
  22. 22.
    Weyand CM, Goronzy J, Fathman CG. Human T-cell clones used to define functional epitopes on HLA class II molecules. Proc Natl Acad Sci USA 1986; 83: 762–766.Google Scholar
  23. 23.
    Numaga J, Matsuki K, Mochizuki M, Minami M, Juji T. An HLA-D region restriction fragment associated with refractory Behçet's disease. Am J Ophthalmol 1988; 105: 528–533.Google Scholar
  24. 24.
    Chan CC, Detrick B, Nussenblatt RB, Palestine AG, Fujikawa LS, Hooks JJ. HLA-DR antigens on retinal pigment epithelial cells from patients with uveitis. Arch Ophthalmol 1986; 104: 725–729.Google Scholar
  25. 25.
    Abi-Hanna D, McCluskey P, Wakefield D. HLA antigens in the iris and aqueous humor gamma Interferon levels in anterior uveitis. Invest Ophthalmol Vis Sci 1989; 30: 990–994.Google Scholar
  26. 26.
    Wacker WB, Donoso LA, Kalsow CM, Yankeelov JA Jr, Organisciak DT. Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol 1977; 119: 1949–1958.Google Scholar
  27. 27.
    Faure JP. Autoimmunity and the retina. Curr Top Eye Res 1980; 2: 215–302.Google Scholar
  28. 28.
    Gery I, Mochizuki M, Nussenblatt RB. Retinal specific antigens and immunopathogenic processes they provoke. In: Osborne N, Chader J (eds). Progress in Retinal Research. Oxford: Pergamon Press, vol 5 1986: 75–109.Google Scholar
  29. 29.
    Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA, Nussenblatt RB. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988; 140: 1490–1495.Google Scholar
  30. 30.
    Donoso LA, Merryman CF, Shinohara T, Dietzschold B, Wistow G, Craft C, Morley W, Henry RT. S-antigen. Identification of the MAbA9-C6 monoclonal antibody binding site and the uveitopathogenic sites. Curr Eye Res 1986; 5: 995–1004.Google Scholar
  31. 31.
    Singh VK, Nussenblatt RB, Donoso LA, Yamaki K, Chan CC, Shinohara T. Identification of a uveitopathogenic and lymphocyte proliferative site in bovine S-antigen. Cell Immunol 1988; 115: 413–419.Google Scholar
  32. 32.
    Sanui H, Redmond TM, Hu LH, Kuwabara T, Margalit H, Cornette JL, Wiggert B, Chader GJ, Gery I. Synthetic peptides derived from IRBP induce EAU and EAP in Lewis rats. Curr Eye Res 1988; 7: 727–735.Google Scholar
  33. 33.
    Nussenblatt RB, Gery I, Ballintine EJ, Wacker WB. Cellular immune responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol 1980; 89: 173–179.Google Scholar
  34. 34.
    Botazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmuity. Lancet 1983; 2: 1115–1119.Google Scholar
  35. 35.
    Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96: 275–282.Google Scholar
  36. 36.
    Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K. Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum 1985; 28: 671–679.Google Scholar
  37. 37.
    Masuda K, Nakajima A. A double masked study of ciclosporin treatment in Behçet's disease. In: Schindler R (ed). Ciclosporin in Autoimmune Diseases. Berlin: Springer Verlag 1985: 162–164.Google Scholar
  38. 38.
    BenEzra D, Nussenblatt RB, Timonen P. Optimal Use of Sandimmun in Endogenous Uveitis. Berlin: Springer Verlag 1988: 14–15.Google Scholar
  39. 39.
    Nussenblatt RB, Caspi RR, Dinning WJ, Palestine AG, Hiestand P, Borel J. A comparison of the effectiveness of Cyclosporine A, D, and G in the treatment of experimental autoimmune uveitis in rats. J Immunopharm 1986; 8: 427–435.Google Scholar
  40. 40.
    Palestine AG, Nussenblatt RB, Chan CC, Hooks JJ, Friedman L, Kuwabara T. Histopathology of the subretinal fibrosis and uveitis syndrome. Ophthalmology 1985; 92: 838–844.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Robert B. Nussenblatt
    • 1
  1. 1.National Eye Inst., NIH, Laboratory of ImmunologyBethesdaUSA

Personalised recommendations